Archive for April, 2013

Which Drug Companies Listed the Most Patents Last Year

This infographic shows the pharmaceutical companies that listed the most patents last year. The companies with the most drug patents listed last year are Novartis, Lilly, Merck,Allergan, Sanofi Aventis Us, Astrazeneca, Glaxosmithkline, Pfizer, Veroscience, andWatson Labss. For more infographics, see the DrugPatentWatch Pharmaceutical Innovation Infographics. Do you have a response to this infographic? Respond in the comments section below.


Biotechnology and Pharmaceutical Industry Infographics

These infographics from DrugPatentWatch.com and BiologicPatentWatch.com track innovation and patent activity in the pharmaceutical and biotechnology industries: Pharmaceutical Innovation Infographics Which Drugs Face Patent Expirations this Month? What are the Top-selling Drugs? How Many Drug Patents Will Expire in the Coming Months? How Many Drug Patents Will Expire in the Coming Years? Which Drugs Have the […]


Cancer remains the dominant disease target for biotech through to 2010

This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology
Cancer remains the dominant disease target for biotech through to 2010
Go to paperABSTRACT: The two leading therapeutic areas for biological products, in t…


After Myriad Oral Argument, Supreme Court Set to Decide Patentability of Isolated Human DNA Molecules

This is a guest post by Morrison & Foerster‘s  Marc A. Hearron, James J. Mullen, III and Matthew I. Kreeger. Do you have a response to this post? Sound off  in the comments section below. The Supreme Court of the United States recently heard oral argument in Association for Molecular Pathology v. Myriad Genetics, Inc. (No. 12-398) to […]


See you at BIO in Chicago

I will be at BIO 2013, representing BiotechBlog, the Journal of Commercial Biotechnology, and Scientific American Worldview. I look forward to meeting new and existing readers. If you have an interest in guest-posting on BiotechBlog, an interest in submitting a paper to the Journal of Commercial Biotechnology, or have perspectives on global biotechnlogy that may […]


Drug Patent Expirations for Mar 25 2013

If your reader cannot render the information below, go to
http://www.DrugPatentWatch.com/innovation to see the latest expirations

DrugPatentWatch -- sales, statistics, drug application<br />
information

Advertise
here

This newsletter is
a free service of DrugPatentWatch

DrugPatentWatch offers comprehensive details on FDA approved drugs,
developers, and their patents





Drug Patent Expirations for March 25 2013

Tradename Applicant Generic Name Patent
Expiration
XOPENEX Sunovion levalbuterol hydrochloride Mar 25, 2013
XOPENEX HFA Sunovion levalbuterol tartrate Mar 25, 2013

*Drugs may be
covered by multiple patents or regulatory protections. See the DrugPatentWatch
database for complete details.



DrugPatentWatch
Infographics

Which pharmaceutical companies recieved the most drug approvals last<br />
year

Which Companies had the Most Drug
Approvals Last Year?

More
infographics &raquo





DrugPatentWatch Serves Your Competitive Intelligence
Needs

Subscribers have
access to valuable datasets, including:
  • Patent litigation
  • Clinical trial information
  • International patent families
  • International patent priority and PCT
    information
  • Patent maintenance
  • Full-text patent downloads
  • Paragraph IV challenges
  • Tentative approvals
  • Drug Master Files
  • Dynamic search capabilities with data
    export
  • More…
See the Database
Preview
and Plan
Comparison
. Contact Us with any
questions.





The above list
does not discriminate between dominant and non-dominant patents. Drugs
listed above may be protected by additional patents and other regulatory
protections. See the DrugPatentWatch
database for complete details

DISCLAIMER:
Although great care is taken in the proper and correct provision of this
service, thinkBiotech LLC does not accept any responsibility for possible
consequences of errors or omissions in the provided information. There is
no warranty that the information contained herein is error free. Users of
this service are advised to seek professional advice and independent
confirmation before acting on any of the provided information. thinkBiotech
LLC reserves the right to amend, extend or withdraw any part or all of the
offered service without notice.
All trademarks and applicant names
are the property of their respective owners or
licensors.


Drug Patent Expirations for Mar 22 2013

If your reader cannot render the information below, go to
http://www.DrugPatentWatch.com/innovation to see the latest expirations

Journal of Commercial Biotechnology

Advertise
here

This newsletter is
a free service of DrugPatentWatch

DrugPatentWatch offers comprehensive details on FDA approved drugs,
developers, and their patents





Drug Patent Expirations for March 22 2013

Tradename Applicant Generic Name Patent
Expiration
RYBIX
ODT
Shionogi Inc tramadol hydrochloride Mar 22, 2013

*Drugs may be
covered by multiple patents or regulatory protections. See the DrugPatentWatch
database for complete details.



DrugPatentWatch
Infographics

Which pharmaceutical companies recieved the most drug approvals last<br />
year

Which Companies had the Most Drug
Approvals Last Year?

More
infographics &raquo





DrugPatentWatch Serves Your Competitive Intelligence
Needs

Subscribers have
access to valuable datasets, including:
  • Patent litigation
  • Clinical trial information
  • International patent families
  • International patent priority and PCT
    information
  • Patent maintenance
  • Full-text patent downloads
  • Paragraph IV challenges
  • Tentative approvals
  • Drug Master Files
  • Dynamic search capabilities with data
    export
  • More…
See the Database
Preview
and Plan
Comparison
. Contact Us with any
questions.





The above list
does not discriminate between dominant and non-dominant patents. Drugs
listed above may be protected by additional patents and other regulatory
protections. See the DrugPatentWatch
database for complete details

DISCLAIMER:
Although great care is taken in the proper and correct provision of this
service, thinkBiotech LLC does not accept any responsibility for possible
consequences of errors or omissions in the provided information. There is
no warranty that the information contained herein is error free. Users of
this service are advised to seek professional advice and independent
confirmation before acting on any of the provided information. thinkBiotech
LLC reserves the right to amend, extend or withdraw any part or all of the
offered service without notice.
All trademarks and applicant names
are the property of their respective owners or
licensors.


The SEC’s enforcement programme on biotechnology’s communications with the investment community

This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology
The SEC’s enforcement programme on biotechnology’s communications with the investment community
Go to paperABSTRACT: The proliferation of biotechnology star…


ISO a Scientific Revolution in Cancer Research

This is a guest post from Susan K Finston, President of Finston Consulting. Do you have a response to Susan’s post? Respond in the comments section below. Even if you have never heard of Thomas Kuhn, your thinking about science has most likely been effected by his theory of what causes paradigm shifts. Over 50 years […]